Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04503668 · ClinicalTrials.gov registry record · Phase 3
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
A Phase 3 study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT04503668 is a Phase 3 study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 62 participants.
The verdict
NCT04503668, a Phase 3 study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin and paclitaxel) every 3 weeks.
Interventions
- DRUG Dexamethasone
- DRUG Ondansetron
- DRUG Olanzapine
- DRUG Neurokinin-1 Receptor Antagonist (NK1-RA)
- DRUG Compazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2024-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04503668
The ClinicalTrials.gov registry entry for NCT04503668 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT04503668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04503668 about?
NCT04503668 is a clinical study titled "Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients". The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin...
What is the current status of trial NCT04503668?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2020-12-28. Estimated completion is 2024-03-11.
What interventions are being tested in trial NCT04503668?
The interventions under investigation include: Dexamethasone (DRUG), Ondansetron (DRUG), Olanzapine (DRUG), Neurokinin-1 Receptor Antagonist (NK1-RA) (DRUG), Compazine (DRUG).
Who is sponsoring clinical trial NCT04503668?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.